Finnish-specific AKT2 gene variant leads to impaired insulin signalling in myotubes

Finnish-specific gene variant p.P50T/AKT2 (minor allele frequency (MAF) = 1.1%) is associated with insulin resistance and increased predisposition to type 2 diabetes. Here, we have investigated in vitro the impact of the gene variant on glucose metabolism and intracellular signalling in human primary skeletal muscle cells, which were established from 14 male p.P50T/AKT2 variant carriers and 14 controls. Insulin-stimulated glucose uptake and glucose incorporation into glycogen were detected with 2-[1,2-3H]-deoxy-D-glucose and D-[14C]-glucose, respectively, and the rate of glycolysis was measured with a Seahorse XFe96 analyzer. Insulin signalling was investigated with Western blotting. The binding of variant and control AKT2-PH domains to phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3) was assayed using PIP StripsTM Membranes. Protein tyrosine kinase and serine-threonine kinase assays were performed using the PamGene® kinome profiling system. Insulin-stimulated glucose uptake and glycogen synthesis in myotubes in vitro were not significantly affected by the genotype. However, the insulin-stimulated glycolytic rate was impaired in variant myotubes. Western blot analysis showed that insulin-stimulated phosphorylation of AKT-Thr308, AS160-Thr642 and GSK3β-Ser9 was reduced in variant myotubes compared to controls. The binding of variant AKT2-PH domain to PI(3,4,5)P3 was reduced as compared to the control protein. PamGene® kinome profiling revealed multiple differentially phosphorylated kinase substrates, e.g. calmodulin, between the genotypes. Further in silico upstream kinase analysis predicted a large-scale impairment in activities of kinases participating, for example, in intracellular signal transduction, protein translation and cell cycle events. In conclusion, myotubes from p.P50T/AKT2 variant carriers show multiple signalling alterations which may contribute to predisposition to insulin resistance and T2D in the carriers of this signalling variant.

[1]  M. McCarthy,et al.  Genome-wide association analysis of type 2 diabetes in the EPIC-InterAct study , 2020, Scientific Data.

[2]  M. Laakso,et al.  Simvastatin profoundly impairs energy metabolism in primary human muscle cells , 2020, Endocrine connections.

[3]  V. M. V. Program.  Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis , 2020 .

[4]  P. Sicinski,et al.  A kinase of many talents: non-neuronal functions of CDK5 in development and disease , 2020, Open Biology.

[5]  J. Baur,et al.  The role of skeletal muscle Akt in the regulation of muscle mass and glucose homeostasis , 2019, Molecular metabolism.

[6]  Anthony J. Payne,et al.  Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps , 2018, Nature Genetics.

[7]  Matthew E Berginski,et al.  Coral: Clear and Customizable Visualization of Human Kinome Data. , 2018, Cell systems.

[8]  D. Riley,et al.  Aberrant DNA damage response and DNA repair pathway in high glucose conditions. , 2018, Journal of cancer research updates.

[9]  K. Itahana,et al.  Emerging Roles of p53 Family Members in Glucose Metabolism , 2018, International journal of molecular sciences.

[10]  H. McClung,et al.  AKT2 is the predominant AKT isoform expressed in human skeletal muscle , 2018, Physiological reports.

[11]  C. Lindgren,et al.  A Partial Loss-of-Function Variant in AKT2 Is Associated With Reduced Insulin-Mediated Glucose Uptake in Multiple Insulin-Sensitive Tissues: A Genotype-Based Callback Positron Emission Tomography Study , 2017, Diabetes.

[12]  A. Villalobo,et al.  Src-family tyrosine kinases and the Ca2+ signal. , 2017, Biochimica et biophysica acta. Molecular cell research.

[13]  Mauricio O. Carneiro,et al.  A Low-Frequency Inactivating AKT2 Variant Enriched in the Finnish Population Is Associated With Fasting Insulin Levels and Type 2 Diabetes Risk , 2017, Diabetes.

[14]  Karen L. Mohlke,et al.  The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases , 2017, Journal of Lipid Research.

[15]  Yong Sun,et al.  The Interplay between Calmodulin and Membrane Interactions with the Pleckstrin Homology Domain of Akt* , 2016, The Journal of Biological Chemistry.

[16]  M. Murphy,et al.  The role of the p53 tumor suppressor in metabolism and diabetes. , 2016, The Journal of endocrinology.

[17]  R. Birge,et al.  Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase , 2016, Cell Communication and Signaling.

[18]  C. Proud,et al.  MNK1 and MNK2 mediate adverse effects of high-fat feeding in distinct ways , 2016, Scientific Reports.

[19]  L. Birnbaumer,et al.  Membrane translocation of TRPC6 channels and endothelial migration are regulated by calmodulin and PI3 kinase activation , 2016, Proceedings of the National Academy of Sciences.

[20]  L. Platanias,et al.  Mnk kinase pathway: Cellular functions and biological outcomes. , 2014, World journal of biological chemistry.

[21]  R. Milo,et al.  Visual account of protein investment in cellular functions , 2014, Proceedings of the National Academy of Sciences.

[22]  S. Ellard,et al.  Activating AKT2 mutation: hypoinsulinemic hypoketotic hypoglycemia. , 2014, The Journal of clinical endocrinology and metabolism.

[23]  H. Koistinen,et al.  Acute exposure to resveratrol inhibits AMPK activity in human skeletal muscle cells , 2012, Diabetologia.

[24]  C. Lipinski,et al.  The Lyn Kinase Activator MLR-1023 Is a Novel Insulin Receptor Potentiator that Elicits a Rapid-Onset and Durable Improvement in Glucose Homeostasis in Animal Models of Type 2 Diabetes , 2012, Journal of Pharmacology and Experimental Therapeutics.

[25]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[26]  Claude Bouchard,et al.  A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance , 2012, Nature Genetics.

[27]  I. Barroso,et al.  An Activating Mutation of AKT2 and Human Hypoglycemia , 2011, Science.

[28]  Bhawna Singh,et al.  Surrogate markers of insulin resistance: A review. , 2010, World journal of diabetes.

[29]  N. Fujii,et al.  Calmodulin-Binding Domain of AS160 Regulates Contraction- but Not Insulin-Stimulated Glucose Uptake in Skeletal Muscle , 2007, Diabetes.

[30]  Kyong-Tai Kim,et al.  Stabilization and activation of p53 induced by Cdk5 contributes to neuronal cell death , 2007, Journal of Cell Science.

[31]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[32]  H. Koistinen,et al.  siRNA-based gene silencing reveals specialized roles of IRS-1/Akt2 and IRS-2/Akt1 in glucose and lipid metabolism in human skeletal muscle. , 2006, Cell metabolism.

[33]  Russell G. Jones,et al.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. , 2005, Molecular cell.

[34]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[35]  Jiri Bartek,et al.  Cell-cycle checkpoints and cancer , 2004, Nature.

[36]  J. Parsons,et al.  Src family kinases, key regulators of signal transduction , 2004, Oncogene.

[37]  S. Gauld,et al.  Src-family kinases in B-cell development and signaling , 2004, Oncogene.

[38]  D. Dunger,et al.  A Family with Severe Insulin Resistance and Diabetes Due to a Mutation in AKT2 , 2004, Science.

[39]  G. Benaim,et al.  Phosphorylation of calmodulin. Functional implications. , 2002, European journal of biochemistry.

[40]  D. James,et al.  The Role of Ca2+ in Insulin-stimulated Glucose Transport in 3T3-L1 Cells* , 2001, The Journal of Biological Chemistry.

[41]  H. Klein,et al.  Insulin signaling and action in cultured skeletal muscle cells from lean healthy humans with high and low insulin sensitivity. , 2000, Diabetes.

[42]  R. Watson,et al.  Calmodulin antagonists inhibit insulin-stimulated GLUT4 (glucose transporter 4) translocation by preventing the formation of phosphatidylinositol 3,4,5-trisphosphate in 3T3L1 adipocytes. , 2000, Molecular endocrinology.

[43]  Y Taya,et al.  The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. , 2000, Genes & development.

[44]  E. Stanley,et al.  Autophosphorylation Induces Autoactivation and a Decrease in the Src Homology 2 Domain Accessibility of the Lyn Protein Kinase (*) , 1995, The Journal of Biological Chemistry.

[45]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[46]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[47]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[48]  D. James,et al.  The Role of Ca 2 1 in Insulin-stimulated Glucose Transport in 3 T 3L 1 Cells * , 2001 .

[49]  C. Wrede,et al.  Free fatty acid-induced inhibition of glucose and insulin-like growth factor I-induced deoxyribonucleic acid synthesis in the pancreatic beta-cell line INS-1. , 2001, Endocrinology.